Topics

TScan Therapeutics Company Profile

06:36 EST 24th February 2020 | BioPortfolio

David Southwell, Chief Executive Officer David Southwell is the Chief Executive Officer of TScan and also serves as a member of the Company’s Board of Directors. Previously, David served as President and Chief Executive Officer of Inotek Pharmaceuticals through Inotek’s merger with Rocket Pharmaceuticals, a gene therapy-based biotechnology company. Previously, Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, until its merger with GlaxoSmithKline plc. and as Executive Vice President and Chief Financial Officer of Sepracor Inc., sold to Dainippon Sumitomo. Mr. Southwell is a member of the Board of Directors of Rocket Pharmaceuticals and PTC Therapeutics, and has also served on the Boards of Directors of Human Genome Sciences, THL Credit Inc., Inventiv Health, Biosphere Medical, Inotek Pharmaceuticals and Spero Therapeutics. In addition, Mr. Southwell serves on the Board of Advisers at the Tuck School at Dartmouth College, from which he received an MBA, and has a BA from Rice University.


News Articles [733 Associated News Articles listed on BioPortfolio]

TScan Lands $48M for Better, Safer T-Cell Receptor Cancer Therapies

Despite the progress of therapies that coax the immune system to fight cancer, these treatments don’t work for all patients. When they are effective, some patients experience serious side effects. T...

Tscan: Tracking down novel T cell targets

Tscan aims to find novel TCR-antigen pairs and avoid off-target toxicities using its peptidome library and screening platform.

TScan Founders Lea Hachigian and Tomasz Kula Named in Forbes 2020 “30 Under 30” List

-Co-founders of TScan Named to Annual List of Pioneers- TScan Therapeutics recognizes its co-founders, Lea Hachigian Ph.D. and Tomasz Kula Ph.D., who were honored as healthcare pioneers in the Forb...

Astellas Venture Management, Pitango Venture Capital and Novartis Institutes for BioMedical Research Lead TScan Series B

- Total Series B Raise of $35 million - TScan Therapeutics today announced the completion of its Series B raise with the inclusion of Novartis Institutes for BioMedical Research (NIBR), Pitango Ven...

TScan Therapeutics Announces Pioneering Publication in Scientific Journal Cell Describing New Methods to Identify Targets for T Cell Receptor Immunotherapy

-The TScan Platform enables discovery of novel TCR Immunotherapies for cancer and infectious diseases -TScan is a genome-wide, high-throughput method to uncover the physiologic targets of T cells,...

July 24 Financial Quick Takes: $500M for Seattle Genetics; plus X-Vax, TScan, Alexion and more

TScan Closes on Series B to Develop Next-Generation Immuno-Oncology Therapies

The company’s focus is on improving immuno-oncology therapies, making them more effective for the patients for whom these new therapies don’t work and by decreasing serious side effects.

TScan Therapeutics Formed to Overcome Challenges of Current Immunotherapies with Novel TCR Discovery Platform and $48 Million in Funding

-Leadership team of David Southwell, CEO; Gavin MacBeath, PhD, CSO; Henry Rath, CBO and Robert Crane, CFO- -TCR platform discovers novel targets for T cell therapy, based on pioneering work of Dr. ...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [453 Associated PubMed Articles listed on BioPortfolio]

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, th...

Measurement of mRNA therapeutics: method development and validation challenges.

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for t...

Dr E. Keith Borden: Inaugural President of the Canadian Association for Population Therapeutics.

Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and Therapeutics.

Metabolism: A Burning Opioid Issue in Obesity Therapeutics.

Food restriction triggers a lowering in body temperature. A new study now provides a mechanism for this process that relies on opioid signaling in the hypothalamus. These observations suggest potentia...

Clinical Trials [210 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1424 Associated Companies listed on BioPortfolio]

TScan Therapeutics

David Southwell, Chief Executive Officer David Southwell is the Chief Executive Officer of TScan and also serves as a member of the Company’s Board of Directors. Previously, David served as Pres...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "TScan Therapeutics" on BioPortfolio

We have published hundreds of TScan Therapeutics news stories on BioPortfolio along with dozens of TScan Therapeutics Clinical Trials and PubMed Articles about TScan Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TScan Therapeutics Companies in our database. You can also find out about relevant TScan Therapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record